基于大量循证医学证据,泽布替尼获得NCCN指南最高级别的临床推荐,确立为CLL/SLL的优先治疗选择,对临床实践有重要指导作用。 参考文献 1.NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2.Tam CS, et al. The Lanc...
基于最新版NCCN指南,CLL/SLL的治疗目前主要依赖于分子靶向药物,特别是新一代BTK抑制剂和BCL-2抑制剂,这些药物被优先推荐用于治疗。对于无17p-/TP53突变的患者,这两类药物的临床证据等级达到了I级。一代BTK抑制剂上市时间较早,但其...
基于大量循证医学证据,泽布替尼获得NCCN指南最高级别的临床推荐,确立为CLL/SLL的优先治疗选择,对临床实践有重要指导作用[7]。 参考文献: [1] NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [2] Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine ...
[12] NCCN Guidelines. B-Cell Lymphomas.V2.2023. [13] NCCN Guidelines. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma.V1.2023. [14] CSCO 淋巴瘤诊疗指南 2023. [15] CSCO 恶性血液病诊疗指南 2023
[11] NCCN Guidelines. Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. V2.2023. [12] NCCN Guidelines. B-Cell Lymphomas.V2.2023. [13] NCCN Guidelines. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma.V1.2023. [14] CSCO 淋巴瘤诊疗指南 2023. ...
目前,泽布替尼一线治疗CLL/SLL和WM已获得国内外权威指南一致认可。《NCCN CLL/SLL指南(2023 v2版)》和《NCCN WM/淋巴浆细胞性淋巴瘤(LPL)指南(2023v1版)》均优先推荐泽布替尼治疗CLL/SLL和WM。《CSCO恶性血液病诊疗指南(2023版)》I级推荐泽布替尼用于一线CLL和WM治疗[8-10]。
A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).
For relapse of disease that occurs more than 3 y later, re-treat with first-line therapy; if relapse occurs after less than 2 y, see the NCCN guidelines for second-line therapies based on age and comorbidities[12] Locoregional radiation therapy is appropriate for patients with Ann Arbor stage...
中华肾脏病杂志 2023,39(01) T淋巴细胞亚群联合炎性指标对脓毒症的辅助诊断及预后评估价值 李丰帆 等 中华预防医学杂志 2022,56(04) 四种预后评分系统在早期无症状慢性淋巴细胞白血病患者中评估价值比较 沙业钦 等 中华血液学杂志 2021,42(10) IPI、NCCN-IPI及年龄调整的IPI评分系统在弥漫大B细胞淋巴瘤患者中的...
Poster: CLL-074: Insights From the informCLL Registry: Real-World Application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)doi:10.1016/S2152-2650(21)01386-0Nilanjan Ghosh...